• SENSEX
    NIFTY 50
Economy

US FDA proposes restricting compounding of 3 drug substances

Updated : August 28, 2018 06:29 AM IST

Those substances included vasopressin, the active ingredient in Endo International Plc's blood pressure drug Vasostrict, which has been the subject of a lawsuit by the company targeting how the FDA regulates drug compounding. Shares of Endo jumped 5 percent.
The other two substances are bumetanide and nicardipine hydrochloride, which the regulator said are also ingredients of one or more FDA-approved drug products.
US FDA proposes restricting compounding of 3 drug substances

You May Also Like

Live TV

recommended for you

Advertisement